Global Vaccine Conjugates Market Size, Share, Forecast Report, 2020-2027

Conjugate vaccines are formed by covalently bonding a weak antigen to the strong antigen. It boosts the hosts’ immune response. Conjugate vaccines are germ specific and can identify targeted germ only, so it can be used as a preventative measure to provide additional protection. Conjugate vaccines are used to treat Hib (Haemophilus influenzae type b) disease, Hepatitis B, HPV (Human papillomavirus), Whooping cough (part of the DTaP combined vaccine), Pneumococcal disease, Meningococcal disease, and Shingles. The rising occurrence of diseases caused by microorganisms, increasing awareness about prevention of infectious diseases, and an increasing number of regulatory approvals to the vaccines are expected to drive the growth of the market. Moreover, rising R&D spending and aggressive strategies adopted by top players such as new product launches are contributing to the growth of the market.

The complex manufacturing procedure, low accessibility of vaccines to rural or remote areas, and recent incidents regarding frauds and malpractice of top vaccine manufacturers may hinder the growth of the market during the assessment period. For instance, in July 2018, Chinese vaccine manufacturer Changchun Changsheng Life Sciences Limited (second largest vaccine manufacturer in China) found guilty of fabricating its manufacturing records and faced legal action.

The global market for vaccine conjugates is expected to register a CAGR of approximately 14.5% during the forecast period, 2018 to 2027.

Segmentation

The global vaccine conjugates market is segmented based on type, disease indication, pathogen type, patient stage, and end-user.

Based on type, the global vaccine conjugates market can be segmented into monovalent conjugate vaccines and multivalent conjugate vaccines.

Based on disease indication, the global vaccine conjugates market can be segmented into pneumococcal, influenza, DTP, meningococcal, and others.

Based on pathogen type, the global vaccine conjugates market can be segmented into bacterial conjugate vaccine, viral conjugate vaccine, and combination (viral and bacterial).

Based on patient stage, the global vaccine conjugates market can be segmented into pediatrics conjugate vaccine and adults conjugate vaccine.

Based on end-user, the global vaccine conjugates market can be segmented into research institutes, academic institutes, pharmaceutical industries, and others
Key Players

Some major players in the global vaccine conjugates market include GlaxoSmithKline plc (U.K.), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), Sanofi Pasteur SA (France), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), Johnson & Johnson (U.S.), Medimmune, LLC (U.S.), Astellas Pharma Inc. (Japan), Serum Institute of India (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Fablife. (India), SutroVax Inc. (U.S), Sinovac Biotech Ltd. (China), and others.

Global Vaccine Conjugates Market, by Type

• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccines

Global Vaccine Conjugates Market, by Disease Indication

• Pneumococcal
• Influenza
• DTP
• Meningococcal
• Others

Global Vaccine Conjugates Market, by Pathogen Type

• Bacterial Conjugate Vaccine
• Viral Conjugate Vaccine
• Combination (Viral and Bacterial)

Global Vaccine Conjugates Market, by Patient Stage

• Pediatrics Conjugate Vaccine
• Adults Conjugate Vaccine

Global Vaccine Conjugates Market, by End-User

• Research Institute
• Academic Institute
• Pharmaceutical Industries
• Others